Showing 5301-5310 of 5644 results for "".
- I-MED Pharma Becomes Authorized Canadian Distributor for OrCam MyEye 2https://modernod.com/news/i-med-pharma-becomes-authorized-canadian-distributor-for-orcam-myeye-2/2476463/I-MED Pharma, a Canadian company specializing in dry eye diagnosis and management, announced the signing of an authorized Canadian distribution agreement with OrCam for its MyEye 2 assistive technology device for the blind and visually impaired. The OrCam MyEye 2 is a tiny, portable, artif
- Alnylam and Regeneron to Partner for RNAi Treatmentshttps://modernod.com/news/alnylam-regeneron-to-partner-for-rnai-treatments/2476457/Alnylam Pharmaceuticals and Regeneron Pharmaceuticals have agreed to jointly develop treatments for eye and central nervous system diseases using gene-silencing technology RNA interference (RNAi). Regeneron will make a $400 million upfront payment to Alnylam and also purchase $400 mill
- James Mazzo Joins Board of Directors at Avellino Labshttps://modernod.com/news/james-mazzo-joins-board-of-directors-at-avellino-labs/2476451/Avellino Labs announced the strategic addition of James V. Mazzo to its board of directors. The partnership will further anchor Avellino Lab’s leadership in developing the science and setting the standard of genetic testing in ophthalmology, according to a company news release.
- Asepticys Files 510k Submission With FDA for TriFlect Disinfection Technologyhttps://modernod.com/news/asepticys-files-510k-submission-with-fda-for-triflect-disinfection-technology/2476450/Asepticys announced the completion of multisite human clinical trials for Asepticys’ novel contact lens care solution containing TriFlect technology. The company has submitted a 510(k) application to the FDA. The clinical trials involved over 320 patients at 12 sites across
- Improved Premium IOLs Will Drive Growth in the Global IOL Market Over the Next 5 Yearshttps://modernod.com/news/improved-premium-iols-will-drive-growth-in-the-global-iol-market-over-the-next-5-years/2476449/Innovation in premium lens technology will fuel patient demand in the global IOL market over the next 5 years, according to a Market Scope report. The improved technology will provide better visu
- Nidek Launches the ARK-F/AR-F Auto Refractometerhttps://modernod.com/news/nidek-launches-the-ark-f-ar-f-auto-refractometer/2476446/Nidek has announced the launch of the ARK-F/AR-F Keratometer and Auto Refractometer. The ARK-F/AR-F features fully-automatic measurement. By placing the chin on the chinrest, the new Nidek eye detection camera
- Ocutrx Vision Technologies Receives Second Patent for Augmented Reality Glasses Eye Tracking Technologyhttps://modernod.com/news/ocutrx-vision-technologies-receives-second-patent-for-augmented-reality-glasses-eye-tracking-technology/2476434/Ocutrx Vision Technologies, a manufacturer of augmented reality (AR) glasses, announced the issuance of the company’s second US patent, which will protect the company’s unique eye tracking technology for patients with macular degeneration and other low vision conditions. The patent applies to bot
- Alcon Announces Timothy Stonesifer as Chief Financial Officerhttps://modernod.com/news/alcon-announces-timothy-stonesifer-as-chief-financial-officer/2476432/Alcon announced that Timothy C. Stonesifer will join the company as its new Senior Vice President and Chief Financial Officer, in conjunction with the company’s April 9 spinoff from Novartis. He will report directly to David Endicott, Alcon’s Chief Executive Officer, and bec
- Allergan and Molecular Partners Announce Topline Safety Results From MAPLE Study of Abicipar Pegolhttps://modernod.com/news/allergan-and-molecular-partners-announce-topline-safety-results-from-maple-study-of-abicipar-pegol/2476430/Allergan and Molecular Partners announced topline safety results from MAPLE, a 28-week open-label study which enrolled 123 age-related neovascular macular degeneration (AMD) patients and evaluated the safety of abicipar produced via a modified manufacturing process. In this single arm study, trea
- Higher Calcium Intake Tied to Slower AMD Progressionhttps://modernod.com/news/higher-calcium-intake-tied-to-slower-amd-progression/2479580/Higher levels of dietary and supplementary calcium intake are associated with a lower risk of progression to late age-related macular degeneration (AMD), according to a secondary analysis of data from a large trial, as reported by Reuters.